Johns Hopkins Diabetes GuideMedicationsObesity

Incretin Mimetics and Amylin Analogues

Ana Emiliano, M.D., Brian Pinto, Pharm.D.
Incretin Mimetics and Amylin Analogues is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please or purchase a subscription.

Johns Hopkins Guides provide diagnosis, management, and treatment guidance for infectious diseases, diabetes, and psychiatric conditions. Explore these free sample topics:

Johns Hopkins Guides

~~ The first section of this topic is shown below ~~

INDICATIONS

FDA

  • Incretin mimetics (exenatide, liraglutide, albiglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
  • Liraglutide (Saxenda): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
  • Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.

~~ To view the remaining sections of this topic, please
or purchase a subscription ~~

Last updated: July 17, 2015